Aptevo Therapeutics Inc.APVONASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank27
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P27
Within normal range
vs 3Y Ago
-2.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2024-15.95%
2023-4.33%
2022-5.85%
20216.40%
2020-27.91%
2019-30.02%
201821.93%
2017-1.68%
2016-15.00%
2015-25.46%